



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 21, 2009

To: Primary Clinical Research Associates

From: Sara Braun
Research Protocol Specialist III

Re: N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The “Recurrent Tissue Specimen Submission Form” has been added to collect tissue at time of recurrence.

Please incorporate this new form into your forms packet. If you have any questions, please feel free to contact me.

Enclosure